Zilico Company

Zilico is developing the next generation of cancer diagnostics that will provide real-time diagnosis for cervical cancer and reduce the inherent subjectivity of current methods. Two applications are under development: the first for the referral market and the second for the screening market.


Connections from

Total Funding: $24 M
Headquarters: Manchester, Manchester, United Kingdom
Funding Status: Corporate Round
Employee Number: 11-50
Estimated Revenue: $1M to $10M
Last Funding Type: Corporate Round
Technology: Biomarkers of Female Cancers
Last Funding Date: 2018-02-04
Investors Number: 8
Founded Date: 2006-01-01
Industry: Longevity